1. Home
  2. JFU vs TLPH Comparison

JFU vs TLPH Comparison

Compare JFU & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 9F Inc.

JFU

9F Inc.

HOLD

Current Price

$2.79

Market Cap

37.4M

Sector

Finance

ML Signal

HOLD

TLPH

Talphera Inc.

HOLD

Current Price

$0.84

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFU
TLPH
Founded
2006
2005
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.4M
37.9M
IPO Year
2018
2010

Fundamental Metrics

Financial Performance
Metric
JFU
TLPH
Price
$2.79
$0.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.5K
184.5K
Earning Date
12-09-2022
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,151,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.38
52 Week High
$9.48
$1.57

Technical Indicators

Market Signals
Indicator
JFU
TLPH
Relative Strength Index (RSI) 38.58 52.69
Support Level $2.43 $0.73
Resistance Level $4.80 $0.88
Average True Range (ATR) 0.45 0.07
MACD 0.00 0.01
Stochastic Oscillator 12.90 77.59

Price Performance

Historical Comparison
JFU
TLPH

About JFU 9F Inc.

9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: